Speakers 2013
-
How to optimize current therapy of G1 patients (chairman)
-
Fibrosis staging: liver biopsy or indirect markers? (chairman)
Presentation
-
AGHEMO Alessio
Italy
-
Genotype 2
Presentation
-
-
State of the art lecture (chairman)
-
Future therapeutic strategies with direct acting antivirals (chairman)
-
IFN-free regimens
Presentation
-
BELHADJ BRIK Najet
Tunisia
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon)
Presentation
-
-
Comment optimiser le traitement des rechuteurs et non répondeurs (French speaking luncheon) (chairman)
Presentation
-
BENHAMOU Yves
France
-
Treat
Presentation
-
-
First line therapy: interferon or analogue?
-
Cirrhosis
Presentation
-
-
Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
-
Cirrhotic patients
Presentation
-
-
Comment optimiser le traitement des rechuteurs et non répondeurs (French speaking luncheon)
Presentation
-
-
How to manage relapsers and non-‐responders to PEG IFN + RBV therapy?
Presentation
-
-
Faut-‐il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
CARDOSO Ana Carolina
Brazil
-
Fibrosis staging: liver biopsy or indirect markers?
Presentation
-
-
How to manage relapsers and non-‐responders to PEG IFN + RBV therapy? (chairman)
Presentation
-
-
The control of HBV related liver disease (chairman)
-
The clinical applications of HBsAg quantification (chairman)
Presentation
-
-
How to optimize current therapy of G1 patients (chairman)
-
First line therapy: interferon or analogue? (chairman)
Presentation
-
-
Predictors of response
-
G1 naive patients: how to optimize treatment? (chairman)
-
The control of HBV related liver disease (chairman)
Presentation
-
-
Fibrosis staging: liver biopsy or indirect markers?
Presentation
-
DELFRAISSY Jean-François
France
-
Research in viral hepatitis: the French ANRS experience
Presentation
-
-
Comment optimiser le traitement des rechuteurs et non répondeurs (French speaking luncheon) (chairman)
Presentation
-
DI MARTINO Vincent
France
-
Triple therapy with telaprevir or boceprevir: management of side effects?
Presentation
-
DUSHEIKO Geoffrey
UK
-
Why do I treat my patient with pegylated IFN?
-
Treatment of patients with resistant HBV? (chairman)
Presentation
-
El RAY Ahmed
Egypt
-
G4 patients: how to optimize treatment?
Presentation
-
-
Genotype 4
-
G4 patients: how to optimize treatment?
Presentation
-
-
New therapeutic strategies (chairman)
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects?
Presentation
-
FLISIAK Robert
Poland
-
Future therapeutic strategies with direct acting antivirals
Presentation
-
-
Genotype 3
-
G4 patients: how to optimize treatment? (chairman)
-
Controversy: F1/F2 patients: treat or wait? (chairman)
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects? (chairman)
-
Difficult to treat patients (chairman)
Presentation
-
-
Should immunotolerant and inactive carriers be treated?
Presentation
-
HAGAN Liesl
USA
-
Future therapeutic strategies with direct acting antivirals
Presentation
-
-
Resistance to protease inhibitors: is it a real issue?
-
The clinical applications of HBsAg quantification
Presentation
-
HEATHCOTE Jenny
Canada
-
Milestones in therapy of liver diseases
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon) (chairman)
Presentation
-
-
G1 naive patients: how to optimize treatment?
Presentation
-
-
Optimal treatment with telaprevir
Presentation
-
-
New therapeutic strategies (chairman)
Presentation
-
-
Why do I treat my patient with a NUC?
Presentation
-
-
Optimal therapy of HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
KRASTEV Zahari
Bulgaria
-
Interféron ou analogue ? (French speaking luncheon) (chairman)
Presentation
-
-
Acute hepatitis B and HBV reactivation
Presentation
-
-
Resistance to protease inhibitors: is it a real issue?
Presentation
-
-
Why do I treat my patient with pegylated IFN?
-
Should immunotolerant and inactive carriers be treated? (chairman)
Presentation
-
-
First line therapy: interferon or analogue?
Presentation
-
-
Management of side effects
-
Should immunotolerant and inactive carriers be treated?
Presentation
-
LEROY Vincent
France
-
Treatment of patients with resistant HBV?
Presentation
-
-
Therapy in special populations (chairman)
Presentation
-
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
LIAW Yun-Fan
Taiwan
-
Impact of therapy on the outcome of CHB
-
Long term impact of treatment on the outcome of the liver disease? (chairman)
Presentation
-
LIM Seng Gee
Singapore
-
Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
MANNS Michael
Germany
-
Optimal treatment with boceprevir
Presentation
-
-
Introduction: Treatment of hepatitis C: the cure
-
State of the art lecture (chairman)
-
Conclusion
-
Introduction: HBV: viral control or clinical cure?
-
Conclusion: the next steps
Presentation
-
-
HBsAg quantitation ; clinical applications
-
The clinical applications of HBsAg quantification
Presentation
-
MATHURIN Philippe
France
-
Long term impact of treatment on the outcome of the liver disease?
Presentation
-
MOUCARI Rami
United Arab Emirates
-
Interféron ou analogue ? (French speaking luncheon)
Presentation
-
-
2nd generation protease inhibitors
Presentation
-
-
Difficult to treat patients (chairman)
Presentation
-
OULD GOUGAM Rachid
Algeria
-
Interféron ou analogue ? (French speaking luncheon)
Presentation
-
PAIS Raluca
France
-
G1 naive patients: how to optimize treatment?
Presentation
-
-
Why do I treat my patient with a NUC?
-
Treatment of patients with resistant HBV?
Presentation
-
PETERSEN Jorg
Germany
-
The role of combination therapy
Presentation
-
-
Pregnancy
Presentation
-
-
Immuno-suppressed patients
Presentation
-
-
Faut-‐il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon)
Presentation
-
RATZIU Vlad
France
-
G1 naive patients: how to optimize treatment? (chairman)
Presentation
-
RICE Charles
USA
-
Targets for HCV therapy: clinical applications
Presentation
-
-
Hepatitis delta
Presentation
-
-
Transplant patients
Presentation
-
SAYEGH Raymond
Lebanon
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon)
Presentation
-
-
How to manage relapsers and non-‐responders to PEG IFN + RBV therapy? (chairman)
-
Optimal therapy of HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
-
Resistance to protease inhibitors: is it a real issue? (chairman)
-
Best strategies for global HCV eradication
Presentation
-
SERFATY Lawrence
France
-
How to manage relapsers and non-‐responders to PEG IFN + RBV therapy?
Presentation
-
-
Treat
Presentation
-
-
HIV co-infected patients
Presentation
-
THURSZ Mark
UK
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
TRAN Albert
France
-
Comment optimiser le traitement des rechuteurs et non répondeurs (French speaking luncheon)
Presentation
-
-
Faut-‐il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon) (chairman)
Presentation
-
YAZDANPANAH Yazdan
France
-
Long term impact of treatment on the outcome of the liver disease?
Presentation
-
-
Interféron ou analogue ? (French speaking luncheon) (chairman)
-
Therapy in special populations (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
Polymerase inhibitors
Presentation
-
ZOULIM Fabien
France
-
Optimal management of patients with resistance
Presentation
-
